From January 18, 2024 to March 31, 2024, the company has repurchased 2,476,300 shares, representing 0.27% for HKD 60.36 million. With this, the company has completed the repurchase of 2,476,300 shares, representing 0.27% for HKD 60.36 million under the buyback announced on January 19, 2024.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
39.89 CNY | +0.45% | +2.92% | +13.94% |
Jun. 06 | Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic | RE |
Jun. 06 | Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.94% | 4.47B | |
+43.64% | 754B | |
+39.42% | 630B | |
-6.58% | 352B | |
+19.72% | 331B | |
+8.78% | 298B | |
+11.92% | 217B | |
-2.62% | 216B | |
+0.03% | 163B | |
+6.13% | 164B |
- Stock Market
- Equities
- 000513 Stock
- News Livzon Pharmaceutical Group Inc.
- Tranche Update on Livzon Pharmaceutical Group Inc.'s Equity Buyback Plan announced on January 19, 2024.